Navigation Links
Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration
Date:2/22/2011

TARRYTOWN, N.Y., Feb. 22, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD).  Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review time from submission to FDA action is ten months.  Regeneron's submission includes a request for Priority Review, which, if granted, would shorten the FDA's targeted goal for review time under PDUFA to six months.

"There have been significant advances in the treatment of wet AMD in recent years.  However, the need for monthly intravitreal injections to obtain optimal vision gains has resulted in a significant burden for physicians, patients, and their caregivers," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.  "We are extremely proud to have conducted the largest global Phase 3 clinical program in patients with wet AMD, which demonstrated that patients treated with VEGF Trap-Eye 2 mg every two months, following three loading doses, were able to be dosed with fewer injections over one year without compromising efficacy.  We look forward to working closely with the FDA to bring this potentially important new medicine to patients with wet AMD."  

The VEGF Trap-Eye BLA is based on the positive results from two Phase 3 trials, the North American VIEW 1 trial and the global VIEW 2 trial.  In these trials, all regimens of VEGF Trap-Eye, including VEGF Trap-Eye dosed 2 milligrams (mg) every two months (following three loading doses), successfully met the primary endpoint of non-inferiority, compared to the current standard of care, ranibizumab 0.5 mg dosed every month.  The primary endpoi
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... BETHLEHEM, Pa. , Nov. 21, 2014 /PRNewswire/ ... drug eluting devices, has developed and manufactured a ... Institute (LPRI), the Research and Development arm of ... Vice President of Project Management at Particle Sciences, ... Particle Sciences utilizing our material sciences and modeling ...
(Date:11/22/2014)... , Nov. 21, 2014 Many ... Undoubtedly, the growing influence of patients in the ... marketing interactions. Now, more than ever, understanding how ... for medical products is essential. ... Practices, LLC, benchmarked companies spent about two-thirds of ...
(Date:11/21/2014)... COLLEGE PARK, Md. , Nov. 21, 2014 /PRNewswire-USNewswire/ ... Engineering today will host the ceremonial groundbreaking of the ... Maryland, College Park. The new building will cultivate transformative ... human health.  Taking place at 10:00 a.m. ... building in the Paint Branch Parking Lot, adjacent to ...
Breaking Medicine Technology:Particle Sciences' Clinical Trial Supplies Group Manufactures Innovative Vaginal Ring 2New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2University of Maryland Breaks Ground for A. James Clark Hall 2University of Maryland Breaks Ground for A. James Clark Hall 3University of Maryland Breaks Ground for A. James Clark Hall 4
... October 25, 2011 International medical ... (NASDAQ OMX Stockholm: SECT B) , announces ... University Hospitals (UH) in Cleveland.   UH and ... medical imaging with the goals of improving patient care, ...
... SUNNYVALE, Calif., Oct. 25, 2011 ... premier radiation oncology company, today announced that the U.S. ... 510(k) clearance to market the Dose Control System (DCS), ... system performance.   The TomoTherapy System revolutionized ...
Cached Medicine Technology:Sectra Signs Medical Imaging Research Agreement With University Hospitals in Cleveland 2Sectra Signs Medical Imaging Research Agreement With University Hospitals in Cleveland 3Accuray Receives 510(k) Clearance for a Rotational Dose Control for the TomoTherapy System 2Accuray Receives 510(k) Clearance for a Rotational Dose Control for the TomoTherapy System 3
(Date:11/22/2014)... PrettyTailor , an outstanding dress ... big promotion. Customers can buy new dresses at its ... visit its website. , As a matter of fact, ... It mainly provides four types of wedding outfits, including ... girl dresses. It also provides a variety of occasion ...
(Date:11/22/2014)... is a famous brand in the bamboo flooring industry. ... bamboo mats ; the new models are offered now ... According to the sales manager of BambooFlooringChina.com, Bamboo is a ... resource. Their bamboo mats are 100% made from natural bamboo. ... bamboo with caramel bamboo strips. , “Bamboo mats ...
(Date:11/22/2014)... Discount-Dress.com is an important company ... is to increase the company’s online market share by a ... of bridesmaid dresses and announced a bridesmaid dress promotion for ... Dec. 30, 2014. All the dresses from this company are ... In fact, Discount-Dress.com is very good at manufacturing wedding dresses. ...
(Date:11/22/2014)... New York, New York (PRWEB) November 22, 2014 ... use of power morcellators ( http://www.morcellatorlawsuit2015.com ) in ... than 450 new signatures since the end of October, ... people had signed the petition as of November 21st, ... October 31st, when 86,042 supporters had signed on to ...
(Date:11/22/2014)... New York, New York (PRWEB) November 22, 2014 ... been filed on behalf of patients who allegedly developed ... move forward in the federal multidistrict litigation now underway ... Liebhard LLP reports. According to court documents, the litigation ... at 10:00 a.m. The Court has directed Lead Counsel ...
Breaking Medicine News(10 mins):Health News:Customers Are Welcome to Shop at PrettyTailor.com 2Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2Health News:Bridesmaid Dresses Introduced by Famous Company Discount-Dress.com For The New Year 2015 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 4Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3
... $12 million grant from the National Institutes of Health ... medication of choice for preventing migraines in children and ... and adolescents in the United States, with an annual ... FDA-approved medication to prevent childhood migraines and there are ...
... experience more chronic musculoskeletal pain, suggests a new study led ... women over the age of 18 were surveyed on their ... the analysis were fibromyalgia, sciatica, chronic neck pain, chronic back ... all over the body. Results showed that women who ...
... Pediatricians in Appalachia are less likely than doctors in ... the human papillomavirus (HPV) vaccine, according to a new study. ... most important risk factor for cervical cancer and studies ... cancer and to die from it than women living elsewhere. ...
... long been an attractive class of drug candidates because ... potential side effects. Dr. Andrei Yudin, Professor, Department ... and effective process that makes linear peptides circular, which ... effectively and increase their stability compared to linear peptides. ...
... By Serena Gordon HealthDay Reporter , TUESDAY, ... colon cancer screening earlier than women, new research suggests. ... have potentially precancerous lesions (also called polyps or adenomas) in ... percent of women -- and to have them at an ...
... documenting patients, preferences for care at the end of life ... A new study published today in the Journal of ... physicians about end-of-life care and have an advance directive in ... do not have these discussions and documents. The study ...
Cached Medicine News:Health News:Cincinnati Children's earns $12 million NIH grant to test migraine prevention medicines 2Health News:Study shows link between smoking and chronic pain in women 2Health News:Pediatricians in Appalachia less likely to recommend HPV vaccine 2Health News:Pediatricians in Appalachia less likely to recommend HPV vaccine 3Health News:OGI and MaRS Innovation invest in peptide therapeutics 2Health News:Do Men Need Colon Cancer Screening Earlier Than Women Do? 2Health News:Do Men Need Colon Cancer Screening Earlier Than Women Do? 3
The Dolphin Medical 2150 Pulse Oximeter consists of the Dolphin ONE OEM 701 Module technology, (1) extension cable, and (1) oximetry sensor to non-invasively calculate the functional saturation of ar...
All-in-One Fingertip Oximeter...
... The Invacare Sleep Printing ... specifically designed to address ... a device that can ... conducting overnight screening for ...
The reliable and easy-to-use 3900/P pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
Medicine Products: